CTOT-45 (Lung Transplantation) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.

What is the Condition Being Studied?

Lung Transplantation

Who Can Participate in the Study?

Adults ages 18+ who are on the list to receive a lung transplant.

For more information about who can join this study, please contact the study team at mailto: kathleen.lane@duke.edu.

Age Group
Adults

What is Involved?

If choose to join this study, you will:

  • Get a random assignment (like a coin flip) to take the study drug or placebo (an inactive substance)
  • Take the study drug or placebo once a month for five months after your lung transplant
  • Have blood draws
  • Have lung biopsy samples collected
  • Have information collected from your medical record
  • Have study visits for up to 3 years after your lung transplant

Study Details

Full Title
TARGETING INFLAMMATION AND ALLOIMMUNITY IN LUNG TRANSPLANT RECIPIENTS WITH TOCILIZUMAB (ALL IN LUNG)
Principal Investigator
Lung Transplant Surgeon
Protocol Number
IRB: PRO00113759
NCT: NCT06033196
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate